XML 25 R14.htm IDEA: XBRL DOCUMENT
v3.24.1.1.u2

INVENTORIES | 3 Months Ended
--- | ---
Mar. 31, 2024
Inventory Disclosure [Abstract] |
INVENTORIES | INVENTORIES Inventories consist of the following as of:
(in thousands) | March 31, 2024 |  | December 31, 2023
Raw materials | $ | 55,115 |  |  | $ | 62,237 |
Packaging materials | 9,854 |  |  | 9,617 |
Work-in-progress | 3,017 |  |  | 3,144 |
Finished goods | 45,851 |  |  | 36,198 |
Inventories | $ | 113,837 |  |  | $ | 111,196 |
Vendor Concentration Raw materials are sourced for products, including active pharmaceutical ingredients (“API”), from both domestic and international suppliers. Generally, only a single source of API is qualified for use in each product due to the cost and time required to validate a second source of supply. As a result, the Company is dependent upon our current vendors to reliably supply the API required for on-going product manufacturing. During the three months ended March 31, 2024, we purchased approximately 25% of our raw material inventory from one supplier. During the three months ended March 31, 2023, no single vendor represented more than 10% of our raw material inventory purchases.

X
- References No definition available. + Details
Name: | us-gaap_InventoryDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//330/tableOfContent + Details
Name: | us-gaap_InventoryDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration